What is Selank being studied for?
Selank is a synthetic seven-amino-acid peptide based on tuftsin, an immune-signalling peptide. Its clinical research has focused on anxiety and related symptoms. Russian product instructions describe a 0.15% nasal-drop preparation containing Selank diacetate.[8]
The appeal is understandable: relief from anxiety with less sedation. Small studies have reported that pattern, but their comparisons, duration and patient groups matter. They do not establish that Selank is an equally effective substitute for every anxiety treatment.
What the anxiety studies found
A 2008 study compared 30 patients receiving Selank with 32 receiving medazepam, a benzodiazepine. Participants had generalized anxiety disorder or neurasthenia, a diagnosis involving fatigue and related symptoms. The investigators reported similar anxiety improvement, with additional effects on fatigue and activity in the Selank group. The accessible abstract gives limited detail for judging blinding and the size of the treatment difference.[1]
A 2014 Russian paper studied 60 adults with anxiety-related disorders. It describes random allocation to Selank or phenazepam, 30 per group, but treatment was open label. Both improved. Phenazepam produced a larger reduction on the reported anxiety scale during the 14-day treatment period. Selank had fewer reported adverse effects, and its anxiety benefit persisted during the following week.[2]
That is a more useful finding than a blanket claim of benzodiazepine-level relief. The study suggests a possible trade-off between the early symptom response and tolerability. Without blinding or a placebo group, expectations and the assessment process could also influence the result.
In 2015, an open-label randomized study compared phenazepam alone in 30 patients with phenazepam plus Selank in 40. The combination produced an earlier response and fewer of several reported adverse effects. After two weeks, half of the combination group continued Selank for another week. That changing treatment schedule matters when interpreting the later results. This was an add-on study, not a test of Selank alone.[3]
Research also extends beyond those frequently cited trials. A 2019 report compared escitalopram plus nasal Selank in 35 patients with escitalopram alone in 20. It reported earlier improvement in anxiety and depressive symptoms over a short follow-up. The paper describes randomized, blinded allocation, but does not adequately explain who remained blinded or describe a matching nasal placebo. It is a preliminary combination finding, not proof that Selank treats depression by itself.[4]
Mechanisms can help explain a result, but do not establish it
Laboratory experiments suggest that Selank can alter GABA receptor binding. GABA is involved in inhibitory signalling in the nervous system. This work offers a possible explanation for anxiety effects; it does not show that Selank works like a benzodiazepine in a person or shares a predictable interaction profile.[5]
Animal findings are also context dependent. A rat experiment found the strongest protection against anxiety-related behaviour with Selank plus diazepam under chronic stress. Repeated administration itself also increased anxiety in animals without the chronic-stress procedure, including saline controls. The authors considered the administration process a source of stress. These findings do not establish how to combine the drugs in people.[6]
A separate study scanned 52 healthy volunteers receiving Selank, Semax or placebo and found changes in brain-network connectivity. It did not test relief of an anxiety disorder or establish a meaningful improvement in daily concentration. A change on a scan is a different outcome from feeling or functioning better.[7]
What do we know about side effects?
The 2014 comparison reported no sedation in the Selank group, but it did report other symptoms, including nasal dryness and some attention, memory or sleep complaints. Fewer adverse effects than a comparator is useful information. It is not the same as no adverse effects.[2]
The Russian instructions list unpleasant taste and possible allergic reactions. They exclude pregnancy, breastfeeding and use under age 18 because efficacy and safety studies are lacking in those groups. The label also says dependence does not occur; the short studies reviewed here do not establish that risk across prolonged use or every preparation.[8]
FDA identifies missing safety information for compounded Selank acetate and potential immune reactions related to peptide aggregation or impurities. A nasal medicine, a differently formulated spray and an injection need their own quality and safety assessment.[9]
A September 2026 preprint reviewed clinical notes about Semax or Selank use. It recorded both perceived benefits and safety concerns, often alongside other peptides. These observations cannot establish which product caused a symptom or how often a reaction would occur. They also do not support an assurance that consumer use is harmless.[11]
Access depends on the country and the preparation
Selank has Russian product instructions for nasal use. That does not confer approval in another country. It is not FDA-approved in the United States, and FDA lists Selank acetate among substances whose compounding nominations were withdrawn, with safety concerns still described.[8][9]
As checked on November 9, 2026, Selank is not one of the six peptides named in the HHS interim compounding policy. The policy includes a specific form of Semax; that does not extend its scope to Selank or a Selank-Semax blend.[10]
How to read the evidence
Anxiety symptoms
Small clinical comparisons report improvement. Several were open label and used another active drug.
Combination studies
Adding Selank to another treatment is a separate question from using it alone.
Brain and lab findings
Receptor and imaging changes provide research clues, not proof of everyday cognitive benefit.
Remaining questions
Longer follow-up, clearer blinding and independent replication would strengthen confidence.
Questions to bring to the clinical conversation
The symptoms
- What diagnosis best explains the anxiety, sleep or concentration problem?
- Which established options have been tried, and what happened?
The product
- What exact preparation and route are proposed?
- Does the supporting study concern the same use, and is access permitted locally?
The plan
- How would current medicines and medical history affect the decision?
- What benefit and adverse effects would be tracked, and when would treatment be reassessed?
What to take away
Selank has human research behind it, including positive anxiety findings. The evidence is still too limited to promise reliable relief without sedation, dependence or other risks. The useful next step is to match a specific symptom and product to the study that actually tested it.
Questions people ask
Is Selank as effective as a benzodiazepine?
Small comparisons reported anxiety improvement, but they do not establish general equivalence. In the 2014 open-label study, phenazepam produced a larger early reduction on the reported anxiety scale, while Selank had fewer adverse effects and a benefit that persisted after treatment.
Has nasal Selank been studied in people?
Yes. The Russian medicine is a nasal-drop preparation, and human studies have used that route, including the 2019 antidepressant add-on study. Those findings cannot automatically be transferred to injections, different sprays or modified versions of the peptide.
Does Selank cause no sedation or dependence?
The small 2014 comparison reported no sedation in its Selank group, and the Russian label states that dependence does not occur. Short trials do not establish an absence of these risks across prolonged use or every preparation. Other symptoms and possible allergic reactions are reported.
Is Selank FDA-approved or covered by the new US peptide policy?
Selank is not FDA-approved. As checked November 9, 2026, it is not listed in the HHS interim policy covering six peptide substances. The inclusion of Semax in that policy does not include Selank or a blend of the two.
The evidence
Sources used for this article. Labels distinguish original clinical studies, laboratory findings, product instructions and regulatory information.
Sources checked November 9, 2026. This focused review uses original Russian reports and product instructions where accessible, alongside indexed abstracts and current US regulatory sources. Translation, access limits and publication-notice searches are recorded in the source review.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Selank is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.